MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202641051088 A) filed by Saveetha Institute Of Medical And Technical on April 22, 2026, for Silyorabase : Muco Adhesive Silymarin Orabase For Management Of Oral Lichen Planus.
Inventors include Dr. E. Thariny; Dr. T N Umamaheswari; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: ABSTRACT Oral lichen planus (OLP) is a chronic, immune-mediated inflammatory disorder of the oral mucosa characterized by recurrent episodes of erythema, ulceration, burning sensation, and pain that interfere with eating, speaking, and overall quality of life. Because of its persistent and relapsing nature, long-term topical therapy is often required to control symptoms and reduce mucosal inflammation. However, conventional topical formulations such as gels, ointments, and mouth rinses have limited clinical effectiveness, as they are rapidly diluted and cleared by saliva and easily displaced _by _110rmal_pral movements. This results in reduced drug residenc_e time_, Jt the lesion site, inadequate therapeutic concentration, frequent reapplication, and decreased patient compliance. The present invention overcomes these limitations through the development of a silymarin-infused mucoadhesive Orabase formulation designed for sustained and localized intraoral drug delivery. Silymarin, a flavonolignan complex derived from Silybum marianum, possesses potent antiinflammatory, antioxidant, immunomodulatory, and tissue-protective properties that help reduce mucosal inflammation, counter oxidative stress, and promete epithelial healing. The Orabase system forms a protective, adhesive barrier over the lesion, enhancing drug retention, preventing salivary washout, and enabling controlled release at the site of application. In addition to improving local bioavailability and therapeutic efficacy, the formulation serves as a steroid-free alternative to conventional corticosteroid therapy, thereby minimizing associated adverse effects and improving patient acceptance. This approach provides a safe, effective, and patient-friendly option for the long-term management of oral lichen planus and other chronic inflammatory conditions of the oral mucosa.
Disclaimer: Curated by HT Syndication.
